Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells

Explaining inter-individual variability in phenotype: Is epigenetics up to the challenge?

(2010) Nahid Turan et al.   Epigenetics

Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy

(2010) B Claes et al.   HEREDITY

Use of Cell Lines in the Investigation of Pharmacogenetic Loci

(2009) Wei Zhang et al.   CURRENT PHARMACEUTICAL DESIGN

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival

(2009) U Mahlknecht et al.   LEUKEMIA

Genetic factors influencing cytarabine therapy

(2009) Jatinder K Lamba   PHARMACOGENOMICS

Pharmacogenomic Discovery Using Cell-Based Models

(2009) M. Welsh et al.   PHARMACOLOGICAL REVIEWS

Detection of Gene Expression in an Individual Cell Type within a Cell Mixture Using Microarray Analysis

(2009) Penelope A. Bryant et al.   PLoS One

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity

(2008) C. M. Hartford et al.   BLOOD

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia

(2008) Deepika Bhatla et al.   BRITISH JOURNAL OF HAEMATOLOGY

Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression

(2008) L. Li et al.   CANCER RESEARCH

Differential Allelic Expression in Leukoblast from Patients with Acute Myeloid Leukemia Suggests Genetic Regulation of CDA, DCK, NT5C2, NT5C3, and TP53

(2008) L. P. Jordheim et al.   DRUG METABOLISM AND DISPOSITION